Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL465908 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL9625167 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL4933917 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL992285 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL1832445 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL292514 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL7090995 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL4784041 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL2031974 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL948 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2530077-B1 | Novel method for preparing imatinib base | BCWORLD PHARM CO LTD (KR) | 2014-01-08 | — | — | EP | disclosed |
| EP-2530077-A1 | Novel method for preparing imatinib base | Bcworld Pharm. Co. Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2044037-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1137640-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000035885-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | ALDH1A1 2535/4885TSHR 4747/4885HSD17B10 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.